JP2020534874A5 - - Google Patents

Download PDF

Info

Publication number
JP2020534874A5
JP2020534874A5 JP2020539127A JP2020539127A JP2020534874A5 JP 2020534874 A5 JP2020534874 A5 JP 2020534874A5 JP 2020539127 A JP2020539127 A JP 2020539127A JP 2020539127 A JP2020539127 A JP 2020539127A JP 2020534874 A5 JP2020534874 A5 JP 2020534874A5
Authority
JP
Japan
Prior art keywords
epitope
antigen
fusion peptide
fusion protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020539127A
Other languages
English (en)
Japanese (ja)
Other versions
JP7146926B2 (ja
JP2020534874A (ja
Filing date
Publication date
Priority claimed from PCT/CN2017/104401 external-priority patent/WO2019061297A1/zh
Application filed filed Critical
Publication of JP2020534874A publication Critical patent/JP2020534874A/ja
Publication of JP2020534874A5 publication Critical patent/JP2020534874A5/ja
Application granted granted Critical
Publication of JP7146926B2 publication Critical patent/JP7146926B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020539127A 2017-09-29 2018-09-28 Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン Active JP7146926B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/104401 2017-09-29
PCT/CN2017/104401 WO2019061297A1 (zh) 2017-09-29 2017-09-29 一种cd4辅助性t细胞表位融合肽及其疫苗
PCT/CN2018/108331 WO2019062853A1 (zh) 2017-09-29 2018-09-28 一种cd4辅助性t细胞表位融合肽及其疫苗

Publications (3)

Publication Number Publication Date
JP2020534874A JP2020534874A (ja) 2020-12-03
JP2020534874A5 true JP2020534874A5 (enExample) 2021-03-11
JP7146926B2 JP7146926B2 (ja) 2022-10-04

Family

ID=65900409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020539127A Active JP7146926B2 (ja) 2017-09-29 2018-09-28 Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン

Country Status (5)

Country Link
US (2) US11352411B2 (enExample)
EP (1) EP3715359A4 (enExample)
JP (1) JP7146926B2 (enExample)
CN (4) CN109575142B (enExample)
WO (3) WO2019061297A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
WO2021087851A1 (zh) * 2019-11-07 2021-05-14 苏州工业园区唯可达生物科技有限公司 一种重组病毒载体、包含其的免疫组合物以及用途
CN110923266A (zh) * 2019-11-07 2020-03-27 苏州工业园区唯可达生物科技有限公司 一种重组病毒载体、包含其的免疫组合物以及用途
CN118221773B (zh) * 2024-02-05 2025-09-09 首都医科大学附属北京儿童医院保定医院 与HLA相关的CMV pp65表位疫苗组合物与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2195642A1 (en) * 1994-07-27 1996-02-08 Andreas Suhrbier Polyepitope vaccines
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
EA006940B1 (ru) * 1998-09-15 2006-06-30 Фармэкса А/С Применение opgl и его аналогов для отрицательной регуляции opgl в организме животного
DE69918146T2 (de) * 1998-10-05 2005-07-07 Pharmexa A/S Verfahren zur therapeutischen impfung
AU2003203140A1 (en) * 2002-01-17 2003-07-30 Pharmexa A/S Immunogenic carcinoembryonic antigen (cea)
US20050221381A1 (en) * 2002-02-28 2005-10-06 Christof Klade Method for isolating ligands
AU2003208314A1 (en) 2002-03-11 2003-09-22 Pharmexa A/S Novel application of vaccination against tnf-alpha
JP2005535627A (ja) 2002-06-25 2005-11-24 シティ・オブ・ホープ アジュバント不含ペプチド・ワクチン
CA2496409A1 (en) 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
CN1517437B (zh) * 2003-01-15 2010-06-09 张聪慧 特异性治疗肿瘤或胞内感染的疫苗及应用
ITMI20031201A1 (it) * 2003-06-13 2004-12-14 Istituto Giannina Gaslini Epitopi della proteina pp65 di citomegalovirus
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20080253993A1 (en) * 2005-03-31 2008-10-16 Pharmexa A/S Immunogenic Egfr Peptides Comprising Foreign T Cell Stimulating Epitope
AU2006312847A1 (en) * 2005-11-09 2007-05-18 Pharmexa A/S Therapeutic vaccines targeting HMGB1
EP2027146B1 (en) 2006-05-30 2012-10-03 Bogoch, Samuel, Dr. Replikin peptides and uses thereof
NZ720288A (en) * 2006-12-27 2020-02-28 Harvard College Compositions and methods for the treatment of infections and tumors
AU2008207025B2 (en) 2007-01-15 2012-08-23 Glaxosmithkline Biologicals Sa Vaccine
US8778847B2 (en) * 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
ES2539818T3 (es) * 2007-08-02 2015-07-06 Biondvax Pharmaceuticals Ltd. Vacunas contra la gripe multiepitópicas multiméricas
US8580276B2 (en) * 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
CN101579527B (zh) * 2009-06-24 2010-10-27 山东大学齐鲁医院 中国人群hla特异人巨细胞病毒多表位腺病毒核酸疫苗
AU2010293059B2 (en) 2009-08-26 2017-03-16 Selecta Biosciences, Inc. Compositions that induce T cell help
WO2011046996A2 (en) * 2009-10-13 2011-04-21 The Johns Hopkins University Consensus sequence for influenza a virus
WO2013093514A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccines - peptides
EP2795321A2 (en) * 2011-12-23 2014-10-29 Retroscreen Virology Ltd Vaccine - screening method
CN102600466B (zh) * 2012-03-23 2014-06-11 河南农业大学 抗甲型流感病毒新型通用表位疫苗及其制备方法
CN103160530B (zh) * 2013-03-19 2017-10-20 苏州工业园区唯可达生物科技有限公司 一种融合基因及其应用
US10435462B2 (en) * 2015-03-31 2019-10-08 Viro Dynamics Corporation Hybrid influenza seed viruses, compositions thereof, and use thereof in the diagnosis or therapy of influenza
JP6989134B2 (ja) 2015-11-18 2022-01-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. ポリｉ：ｃポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
CN110923266A (zh) * 2019-11-07 2020-03-27 苏州工业园区唯可达生物科技有限公司 一种重组病毒载体、包含其的免疫组合物以及用途

Similar Documents

Publication Publication Date Title
JP2020534874A5 (enExample)
JP6957580B2 (ja) 新規多価ナノ粒子に基づくワクチン
Donnelly et al. DNA vaccines
Rosendahl Huber et al. T cell responses to viral infections–opportunities for peptide vaccination
Gupta et al. Recent advances in cancer vaccines: challenges, achievements, and futuristic prospects
Ada Vaccines and vaccination
Hanke Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines
Park et al. Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells
JP2008530245A5 (enExample)
Al-Barwani et al. Antigen delivery by virus-like particles for immunotherapeutic vaccination
JP2016128513A5 (enExample)
JP2019526580A5 (enExample)
JP2015509707A5 (enExample)
JP2013532971A5 (enExample)
Kim et al. DNA vaccines against influenza viruses
JP2017515508A5 (enExample)
Mohan et al. Nasal delivery of PLG microparticle encapsulated defensin peptides adjuvanted gp41 antigen confers strong and long-lasting immunoprotective response against HIV-1
JP2020534874A (ja) Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン
Wang et al. M cell DNA vaccination for CTL immunity to HIV
JP2016520534A5 (enExample)
RU2019113989A (ru) Лекарственное средство
JP2019536473A5 (enExample)
Zinkernagel Immunity, immunopathology and vaccines against HIV?
Eisenhut et al. COVID-19 vaccines and coronavirus 19 variants including alpha, delta, and omicron: present status and future directions
Pattinson et al. Chimeric virus-like particles and Capsomeres induce similar CD8+ T cell responses but differ in capacity to induce CD4+ T cell responses and antibody responses